Literature DB >> 30593216

Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial: Erratum.

.   

Abstract

Entities:  

Year:  2018        PMID: 30593216      PMCID: PMC6314773          DOI: 10.1097/MD.0000000000013948

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


× No keyword cloud information.
In the article, “Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial”,[ which appeared in Volume 97, Issue 45 of Medicine, the disclosure statement should be “The authors report no other conflicts of interest.” In Figure 5, the label for the first group should be HIV+ART+” instead of “HIV+ART−“. In the caption for Figure 6, “D6 = 30 days post-dose 2” should be “D60 = 30 days post-dose 2”.
  1 in total

1.  Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial.

Authors:  Nagalingeswaran Kumarasamy; Selvamuthu Poongulali; Faith Esther Beulah; Elaine Jacqueline Akite; Leo Njock Ayuk; Anne Bollaerts; Marie-Ange Demoitié; Erik Jongert; Opokua Ofori-Anyinam; Olivier Van Der Meeren
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.